Scolaris Content Display Scolaris Content Display

Reference flow
Figures and Tables -
Figure 1

Reference flow

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figures and Tables -
Figure 2

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figures and Tables -
Figure 3

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Comparison 1 Intervention versus control, Outcome 1 90‐day mortality.
Figures and Tables -
Analysis 1.1

Comparison 1 Intervention versus control, Outcome 1 90‐day mortality.

Comparison 1 Intervention versus control, Outcome 2 Mortality at maximal follow‐up.
Figures and Tables -
Analysis 1.2

Comparison 1 Intervention versus control, Outcome 2 Mortality at maximal follow‐up.

Comparison 1 Intervention versus control, Outcome 3 Mortality (hazard ratio).
Figures and Tables -
Analysis 1.3

Comparison 1 Intervention versus control, Outcome 3 Mortality (hazard ratio).

Comparison 1 Intervention versus control, Outcome 4 90‐day retransplantation.
Figures and Tables -
Analysis 1.4

Comparison 1 Intervention versus control, Outcome 4 90‐day retransplantation.

Comparison 1 Intervention versus control, Outcome 5 Re‐transplantation at maximal follow‐up.
Figures and Tables -
Analysis 1.5

Comparison 1 Intervention versus control, Outcome 5 Re‐transplantation at maximal follow‐up.

Comparison 1 Intervention versus control, Outcome 6 Graft rejection requiring re‐transplantation.
Figures and Tables -
Analysis 1.6

Comparison 1 Intervention versus control, Outcome 6 Graft rejection requiring re‐transplantation.

Comparison 1 Intervention versus control, Outcome 7 Graft rejection requiring steroids or equivalent drugs.
Figures and Tables -
Analysis 1.7

Comparison 1 Intervention versus control, Outcome 7 Graft rejection requiring steroids or equivalent drugs.

Comparison 1 Intervention versus control, Outcome 8 Graft rejection (others).
Figures and Tables -
Analysis 1.8

Comparison 1 Intervention versus control, Outcome 8 Graft rejection (others).

Comparison 1 Intervention versus control, Outcome 9 Cessation of treatment.
Figures and Tables -
Analysis 1.9

Comparison 1 Intervention versus control, Outcome 9 Cessation of treatment.

Comparison 1 Intervention versus control, Outcome 10 Reduction in dose.
Figures and Tables -
Analysis 1.10

Comparison 1 Intervention versus control, Outcome 10 Reduction in dose.

Comparison 1 Intervention versus control, Outcome 11 Anaemia.
Figures and Tables -
Analysis 1.11

Comparison 1 Intervention versus control, Outcome 11 Anaemia.

Comparison 1 Intervention versus control, Outcome 12 Leukopenia.
Figures and Tables -
Analysis 1.12

Comparison 1 Intervention versus control, Outcome 12 Leukopenia.

Comparison 1 Intervention versus control, Outcome 13 Renal failure.
Figures and Tables -
Analysis 1.13

Comparison 1 Intervention versus control, Outcome 13 Renal failure.

Comparison 1 Intervention versus control, Outcome 14 Depression.
Figures and Tables -
Analysis 1.14

Comparison 1 Intervention versus control, Outcome 14 Depression.

Comparison 1 Intervention versus control, Outcome 15 Rapid virological response.
Figures and Tables -
Analysis 1.15

Comparison 1 Intervention versus control, Outcome 15 Rapid virological response.

Comparison 1 Intervention versus control, Outcome 16 Early virological response.
Figures and Tables -
Analysis 1.16

Comparison 1 Intervention versus control, Outcome 16 Early virological response.

Comparison 1 Intervention versus control, Outcome 17 End of treatment virological response.
Figures and Tables -
Analysis 1.17

Comparison 1 Intervention versus control, Outcome 17 End of treatment virological response.

Comparison 1 Intervention versus control, Outcome 18 Sustained virological response.
Figures and Tables -
Analysis 1.18

Comparison 1 Intervention versus control, Outcome 18 Sustained virological response.

Comparison 1 Intervention versus control, Outcome 19 Virological titre at maximal follow‐up.
Figures and Tables -
Analysis 1.19

Comparison 1 Intervention versus control, Outcome 19 Virological titre at maximal follow‐up.

Comparison 1 Intervention versus control, Outcome 20 Recurrence (hazard ratio).
Figures and Tables -
Analysis 1.20

Comparison 1 Intervention versus control, Outcome 20 Recurrence (hazard ratio).

Comparison 1 Intervention versus control, Outcome 21 Fibrosis worsening.
Figures and Tables -
Analysis 1.21

Comparison 1 Intervention versus control, Outcome 21 Fibrosis worsening.

Comparison 1 Intervention versus control, Outcome 22 Fibrosis score at maximal follow‐up.
Figures and Tables -
Analysis 1.22

Comparison 1 Intervention versus control, Outcome 22 Fibrosis score at maximal follow‐up.

Comparison 1 Intervention versus control, Outcome 23 Activity worsening.
Figures and Tables -
Analysis 1.23

Comparison 1 Intervention versus control, Outcome 23 Activity worsening.

Comparison 1 Intervention versus control, Outcome 24 Activity score at maximal follow‐up.
Figures and Tables -
Analysis 1.24

Comparison 1 Intervention versus control, Outcome 24 Activity score at maximal follow‐up.

Comparison 1. Intervention versus control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 90‐day mortality Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Interferon versus control

1

81

Risk Ratio (M‐H, Fixed, 95% CI)

1.31 [0.41, 4.19]

1.2 HCV antibody versus placebo

2

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.15, 3.11]

1.3 HCV antibody (high dose) versus HCV antibody (low dose)

2

31

Risk Ratio (M‐H, Fixed, 95% CI)

2.75 [0.30, 25.35]

2 Mortality at maximal follow‐up Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.05, 5.59]

2.2 Interferon versus control

2

105

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.36, 2.08]

3 Mortality (hazard ratio) Show forest plot

1

Hazard Ratio (Fixed, 95% CI)

Subtotals only

3.1 Interferon versus control

1

Hazard Ratio (Fixed, 95% CI)

0.45 [0.13, 1.56]

4 90‐day retransplantation Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 HCV antibody versus control

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

1.71 [0.09, 32.93]

4.2 HCV antibody (high dose) versus HCV antibody (low dose)

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

3.0 [0.15, 61.74]

5 Re‐transplantation at maximal follow‐up Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Interferon versus control

2

105

Risk Ratio (M‐H, Fixed, 95% CI)

1.17 [0.22, 6.20]

6 Graft rejection requiring re‐transplantation Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Interferon versus control

1

31

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Interferon and ribavirin versus control

1

32

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.3 Ribavirin and interferon versus interferon

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Graft rejection requiring steroids or equivalent drugs Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.20, 3.27]

7.2 Interferon versus control

3

136

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.68, 1.51]

7.3 Interferon and ribavirin versus control

1

32

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.4 Ribavirin and interferon versus interferon

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Graft rejection (others) Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.21 [0.01, 4.28]

8.2 Pegylated interferon and ribavirin versus control

1

102

Risk Ratio (M‐H, Fixed, 95% CI)

0.59 [0.10, 3.40]

8.3 Interferon versus control

1

31

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.4 Ribavirin versus control

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.23, 5.09]

8.5 Interferon and ribavirin versus control

1

32

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.6 Ribavirin and interferon versus interferon

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Cessation of treatment Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.44, 2.11]

9.2 Interferon versus control

1

81

Risk Ratio (M‐H, Fixed, 95% CI)

27.42 [1.66, 452.50]

9.3 Ribavirin versus control

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

2.25 [0.10, 49.04]

9.4 HCV antibody versus placebo

2

42

Risk Ratio (M‐H, Fixed, 95% CI)

2.49 [0.52, 11.98]

9.5 HCV antibody (high dose) versus HCV antibody (low dose)

2

31

Risk Ratio (M‐H, Fixed, 95% CI)

1.97 [0.60, 6.45]

10 Reduction in dose Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

24.70 [1.53, 399.19]

10.2 Ribavirin versus control

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

5.25 [0.31, 89.35]

10.3 Ribavirin and interferon versus interferon

1

44

Risk Ratio (M‐H, Fixed, 95% CI)

1.18 [0.91, 1.53]

10.4 HCV antibody versus placebo

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

5.71 [0.89, 36.82]

10.5 HCV antibody (high dose) versus HCV antibody (low dose)

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

1.25 [0.64, 2.44]

11 Anaemia Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.43 [0.09, 2.03]

11.2 Pegylated interferon and ribavirin versus control

1

102

Risk Ratio (M‐H, Fixed, 95% CI)

8.0 [1.05, 60.86]

11.3 Ribavirin versus control

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

6.75 [0.41, 110.01]

11.4 Interferon and ribavirin versus control

1

32

Risk Ratio (M‐H, Fixed, 95% CI)

13.64 [0.88, 210.72]

12 Leukopenia Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [0.45, 3.73]

12.2 Interferon versus control

1

24

Risk Ratio (M‐H, Fixed, 95% CI)

5.0 [0.27, 94.34]

13 Renal failure Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.43 [0.09, 2.03]

14 Depression Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

1.79 [0.48, 6.77]

14.2 Pegylated interferon and ribavirin versus control

1

102

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

15 Rapid virological response Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

15.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.76, 1.03]

15.2 Pegylated interferon and ribavirin versus control

1

115

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.86, 1.01]

16 Early virological response Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

16.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.71, 1.01]

16.2 Pegylated interferon and ribavirin versus control

1

115

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.72, 0.98]

17 End of treatment virological response Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

17.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.71, 1.01]

17.2 Interferon versus control

1

81

Risk Ratio (M‐H, Fixed, 95% CI)

0.63 [0.39, 1.04]

17.3 Ribavirin and interferon versus interferon

1

44

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.63, 1.03]

17.4 HCV antibody versus placebo

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.74, 1.35]

17.5 HCV antibody (high dose) versus HCV antibody (low dose)

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.75, 1.34]

18 Sustained virological response Show forest plot

8

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

18.1 Pegylated interferon versus control

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.81, 1.05]

18.2 Pegylated interferon and ribavirin versus control

1

115

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.71, 0.96]

18.3 Interferon versus control

2

55

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.70, 1.39]

18.4 Ribavirin versus control

1

32

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.56, 1.30]

18.5 Interferon and ribavirin versus control

1

32

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.73, 1.22]

18.6 Ribavirin and interferon versus interferon

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.59, 1.20]

18.7 HCV antibody versus placebo

3

58

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.84, 1.19]

18.8 HCV antibody (high dose) versus HCV antibody (low dose)

3

40

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.85, 1.17]

19 Virological titre at maximal follow‐up Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

19.1 Pegylated interferon versus control

1

54

Mean Difference (IV, Fixed, 95% CI)

0.20 [‐1.35, 1.75]

20 Recurrence (hazard ratio) Show forest plot

2

Hazard Ratio (Fixed, 95% CI)

Subtotals only

20.1 Interferon versus control

2

Hazard Ratio (Fixed, 95% CI)

0.87 [0.61, 1.24]

21 Fibrosis worsening Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

21.1 HCV antibody versus placebo

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.17, 4.43]

21.2 HCV antibody (high dose) versus HCV antibody (low dose)

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.02, 6.86]

22 Fibrosis score at maximal follow‐up Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

22.1 Pegylated interferon versus control

1

54

Mean Difference (IV, Fixed, 95% CI)

‐0.50 [‐1.21, 0.21]

23 Activity worsening Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

23.1 Ribavirin versus control

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.67, 1.78]

23.2 HCV antibody versus placebo

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

1.75 [0.51, 5.98]

23.3 HCV antibody (high dose) versus HCV antibody (low dose)

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

1.33 [0.50, 3.55]

24 Activity score at maximal follow‐up Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

24.1 Pegylated interferon versus control

1

54

Mean Difference (IV, Fixed, 95% CI)

‐1.70 [‐4.06, 0.66]

Figures and Tables -
Comparison 1. Intervention versus control